The guideline rests on a simple but radical premise. Malignant tumors are so complex and heterogeneous that a disease-centric model of care is no longer sufficient; instead, clinicians must adopt a patient-centric paradigm built on what the authors call cancer holistic integrative assessment, or CHIA. CHIA is characterized by four core principles: an integrative philosophy that treats the patient as a whole, multidimensional evaluation spanning clinical history to molecular biology, a dynamic and individualized process that is repeated throughout the disease course, and multidisciplinary collaboration among oncologists, psycho-oncologists, nutritionists, traditional Chinese medicine practitioners, and reproductive medicine specialists. Assessment, in this framework, is both a diagnostic procedure and a strategy to preemptively avoid treatment-induced injury.

The intellectual lineage of the guideline traces back to the mid-twentieth century, when tumor assessment focused almost exclusively on tumor size and morphology, exemplified by the 1979 WHO criteria for solid tumor response. The introduction of RECIST 1.0 in 2000 by the EORTC, U.S. NCI, and NCIC provided a simplified, reproducible measurement method, and the arrival of targeted and immune therapies later spawned newer criteria such as Choi, mRECIST, irRC, and iRECIST. In parallel, symptom-management assessment gained prominence: the Brief Pain Inventory quantified subjective pain, the Distress Thermometer enabled rapid psychological screening, and tools such as NRS-2002 and PG-SGA brought evidence-based nutritional risk assessment into routine practice. The CACA guideline weaves these threads into a single, unified pre-therapy evaluation framework.

The urgency of the effort is underscored by a nationwide survey conducted between September 2023 and February 2024 involving 2,236 healthcare professionals. The results revealed striking practice gaps: only 38.08 percent of respondents assessed performance status in every patient, psychosocial screening was offered in fewer than half of units for 61.28 percent of respondents, and genetic-risk assessment was performed in more than 10 percent of units by just 17.69 percent. While nursing assessments of pain and nutrition were robust, with coverage above 83 percent, and physician-led comorbidity assessment was common at 89.49 percent, significant barriers persisted. Roughly a third of professionals lacked knowledge or skills, 35.26 percent had no relevant training, nearly 20 percent cited absent guidelines, and almost half reported time constraints. The authors distill these obstacles into three phrases: “don’t know how,” “no time,” and “no standards.”

Technically, the guideline is remarkably granular. For general status, it mandates that evaluations of physical function, symptoms, and nutrition be completed within 24 hours of admission for inpatients. Performance status is appraised with the Karnofsky scale, scored 0 to 100 across 11 levels, and the simpler ECOG scale, scored 0 to 5, whose 1594 trial established ECOG 2 or higher as a cutoff indicating no benefit from chemotherapy in advanced non-small-cell lung cancer. For older adults, the Timed Up and Go test quantifies mobility and balance, with times under 10 seconds indicating good mobility and times over 20 seconds prompting deeper assessment. The guideline is careful to note that these scores are reference rather than absolute criteria: a breast cancer patient with a pathologic femoral fracture may still warrant surgery despite a Karnofsky score of 30, and a patient with small-cell lung cancer and ECOG 3 may still benefit from chemotherapy.

Organ function assessment occupies a central chapter. Cardiac evaluation relies on echocardiography, electrocardiography, and biomarkers such as troponin and brain natriuretic peptide, with risk-stratified monitoring schedules tied to left ventricular ejection fraction; a decline of more than 10 percent during therapy triggers treatment discontinuation and cardiopulmonary protection. Pulmonary assessment addresses the growing threat of drug-induced interstitial lung disease from chemotherapy, antibody-drug conjugates, and immunotherapy, recommending early high-resolution CT, which offers sensitivity above 90 percent, when new respiratory symptoms follow drug exposure. For thoracic surgery, the guideline integrates the Cardiopulmonary Risk Index and cardiopulmonary exercise testing, flagging high risk when FEV1 falls below 1.5 liters, DLCO below 60 percent, or VO2max below 10 mL/kg/min. Liver function is classified with the Child-Pugh system, kidney function tracked through glomerular filtration rate, and bone marrow readiness defined by thresholds such as an absolute neutrophil count of at least 1.5 × 10⁹ per liter and platelets of at least 80 × 10⁹ per liter.

Perhaps the most forward-looking sections address psychology and social context. In China, 30 to 50 percent of cancer patients experience psychological problems, and the guideline prescribes screening with the Distress Thermometer, the GAD-7 anxiety questionnaire, and depression instruments such as the PHQ-9 and HADS. Cognitive impairment receives unusual attention: 30 to 40 percent of patients show tumor-related cognitive deficits before chemotherapy, 75 percent decline during treatment, and 60 percent decline afterward, with the Mini-Mental State Examination and Montreal Cognitive Assessment serving as core tools. Sleep disorders, affecting 30 to 93.5 percent of cancer patients—roughly three times the general population—are screened with the Insomnia Severity Index and Pittsburgh Sleep Quality Index. Strikingly, the guideline also endorses novel digital tools, including a multimodal psychological system that digitizes the PHQ-9 and GAD-7 and integrates heart-rate variability monitoring; clinical data cited show that this approach raised the objective response rate to immunotherapy in advanced lung cancer from 19.3 to 34.7 percent, and virtual-reality simulation of radiotherapy environments reduced treatment-related adverse events by 41 percent.

The guideline extends assessment into domains most oncology frameworks ignore. Family and social support are quantified with validated instruments including the SCNS-SF34 needs survey, the F-COPES family coping scale, and the CSNAT caregiver tool, with family members of advanced cancer patients explicitly designated as “indirect patients” given their elevated rates of depression and anxiety. Financial toxicity is measured with the COST-PROM instrument, where scores of 22 or below indicate high financial toxicity. Tumor biology is assessed through TNM staging and molecular subtyping, drawing on landmark Chinese multi-omics work in hepatocellular carcinoma, triple-negative breast cancer, and esophageal cancer. Genetic risk chapters cover BRCA1/2-associated hereditary breast and ovarian cancer, where cumulative breast cancer risk by age 80 reaches 72 percent for BRCA1 carriers, along with Lynch syndrome, familial adenomatous polyposis, hereditary thyroid, prostate, gastric, and pancreatic cancers. Fertility protection is framed as a mandatory consideration: an early survey found that although 92 percent of young oncology patients desired children, only 20 percent retained fertility, and the guideline stratifies gonadotoxic risk by drug class and radiation dose.

Uniquely, the document closes with a traditional Chinese medicine framework, defining eight core pathogenesis patterns—qi deficiency, yang deficiency, yin deficiency, blood deficiency, qi stagnation, phlegm-dampness, blood stasis, and heat toxin—and introducing the TCM Eight-Principle Syndrome Quantitative Evaluation Tool, a 100-point instrument with basic, tongue, and pulse modules that generates radar charts for dynamic monitoring. The authors acknowledge that implementation remains the central challenge, calling for strengthened training, guideline dissemination, streamlined workflows, and digital tools. But their ambition is unmistakable: with systematic, standardized, and dynamic holistic integrative assessment, they contend, oncology can move from empirical to precision medicine, delivering care that is simultaneously safer, more effective, and more humanistic—and advancing China’s strategic “Healthy China” goal in the process.

Beyond the enumerated scales and thresholds, the guideline reflects a broader shift in how assessment itself is conceptualized. Rather than a single checkpoint before therapy begins, CHIA is framed as a continuously repeated cycle in which findings feed back into evolving treatment decisions. This dynamic quality distinguishes it from static staging systems, since a patient’s nutritional state, psychological distress, and organ reserve can change substantially between treatment lines, meaning that an assessment performed once at diagnosis may quickly become obsolete.

The document also clarifies how different assessment domains interact in practice. Comorbidity and organ-function findings determine not only whether a therapy is tolerable but which modality is preferable, while family support and financial toxicity shape whether a prescribed regimen can realistically be completed. This interdependence explains why the authors insist on multidisciplinary execution rather than assessment by a single clinician, and why nursing-led screening for pain and nutrition complements physician-led evaluation of comorbidities rather than duplicating it.

The survey findings embedded in the guideline suggest that the main obstacles to adoption are organizational rather than conceptual. Because most respondents already recognized the value of comprehensive evaluation, the authors emphasize practical remedies: embedding standardized protocols into clinical workflows, offering structured training to close knowledge gaps, and deploying digital tools that automate data collection and display results in interpretable formats. Such measures respond directly to the twin barriers of limited time and absent standards.

As integrative oncology matures, frameworks of this kind may serve as templates for other health systems seeking to operationalize patient-centered care. By consolidating validated instruments across physical, psychological, social, genetic, and traditional medicine domains into one coherent process, the guideline demonstrates that holistic assessment can be systematic and measurable rather than aspirational, offering a concrete pathway from whole-person philosophy to everyday clinical decision-making.

Subject of Research: Cancer holistic integrative assessment guidelines for patient-centered oncology evaluation

Article Title: CACA Guidelines for holistic integrative assessment (2025)

Article References: Zhang, H., Shi, Q., Li, X., Li, Q., Liu, Y., Zhang, H., Lin, R., Zhou, W., Chu, Q., Min, J., Zheng, J., Liu, B., Chen, X., He, Y., Ni, L., Li, M., Cong, M., Liang, F., Wang, X., … Liu, D. (2026). CACA Guidelines for holistic integrative assessment (2025). Holistic Integrative Oncology, 5(1), Article 70. https://doi.org/10.1007/s44178-026-00277-6

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00277-6

Keywords: CACA guidelines, holistic integrative oncology, cancer assessment, performance status, psycho-oncology, financial toxicity, genetic risk, fertility preservation, traditional Chinese medicine, precision oncology, China Anti-Cancer Association, patient-centered care

Long-term cancer survivors often grapple with a spectrum of persistent physical ailments, psychological stress, and socio-economic difficulties that standard healthcare models are ill-equipped to address comprehensively. The OPTILATER study emerges against this backdrop of inadequacy, seeking to quantify and qualify the lived experiences of survivors from diverse backgrounds across Germany. By focusing explicitly on long-term survivors, the research confronts a demographic that has been historically underrepresented in clinical studies and healthcare planning.

Set to enroll up to 3,300 cancer survivors who have navigated several years beyond their initial diagnosis and treatment, the study’s cross-sectional survey will collect detailed quantitative data on multiple dimensions of survivorship. These dimensions include critical lifestyle factors such as diet and exercise, mental health status, sleep quality, cognitive function, and overall health-related quality of life. By incorporating assessments of somatic late effects directly attributable to cancer therapies, the study can provide granular insights into the physiological toll that cancer treatment imprints on survivors.

The inclusivity embedded in the OPTILATER protocol is particularly noteworthy, as it deliberately targets participants from various socio-demographic sectors, including those with migration histories. This approach acknowledges the intersectionality of survivorship experiences and the heightened vulnerability some groups face in accessing adequate post-cancer care. With cultural and socio-economic diversities factored into the data set, the study’s outcomes will be pivotal in crafting tailored intervention strategies that reflect real-world heterogeneity.

Technical rigor defines the study’s methodology. Employing structured, validated instruments standardized for epidemiological surveys, the research ensures high-fidelity data capture and reliability. The quantitative survey technique enables statistical analysis to identify correlations and patterns that qualitative approaches might overlook, offering a robust evidence base for health policy recommendations.

Moreover, OPTILATER is registered under the German Clinical Trials Register (DRKS00032146), ensuring transparency and adherence to ethical standards in research. This registration also facilitates the traceability and credibility essential for subsequent peer-reviewed dissemination and validation of findings.

One of the most impactful aspects of this protocol is its potential to influence healthcare policies and clinical guidelines directly. By elucidating the gaps in existing care models, especially for survivors dealing with cognitive impairments, sleep disturbances, and mental health challenges, OPTILATER seeks to bridge the divide between cancer survival and quality of life. The integration of findings into patient-centered care frameworks could revolutionize support systems, enhancing both clinical outcomes and societal reintegration for survivors.

A key focus area of the study is mental health, recognizing that psychological sequelae such as anxiety, depression, and post-traumatic stress disorder remain underreported and insufficiently managed in traditional oncology follow-ups. By quantitatively mapping mental health trajectories across years post-treatment, the research promises to highlight underserved needs and advocate for integrated psycho-oncological services.

The study’s exploration of somatic late effects accounts for a wide range of possible conditions including chronic pain, fatigue, neuropathy, and secondary malignancies. These morbidities can significantly erode functional independence and exacerbate co-morbid conditions, yet they often slip under the radar of routine healthcare provision. OPTILATER’s comprehensive investigation offers a nuanced understanding essential for designing targeted rehabilitative and supportive care interventions.

Further enriching the research scope is its inclusion of lifestyle factors—diet and exercise—that are known modulators of cancer recurrence risk and overall health. By capturing data on these behaviors, the study aligns survivorship research with emerging paradigms emphasizing preventive health and health promotion beyond the acute treatment phase.

Sleep and cognitive evaluations add a cutting-edge dimension to the protocol. Growing evidence indicates that sleep disorders and cognitive decline are prevalent yet neglected domains in survivorship, with implications for daily functioning and quality of life. OPTILATER’s detailed assessment of these factors could pioneer new pathways for symptom management and rehabilitation.

The focus on health-related quality of life (HRQoL) serves as a comprehensive endpoint bridging physical, psychological, and social wellness aspects. This holistic assessment recognizes that survival statistics alone are insufficient measures of cancer care success; the lived experience of survivors defines the true impact of oncological interventions.

By engaging a large, heterogeneous cohort across Germany, this cross-sectional study will also offer invaluable epidemiological data quantifying survivor distribution and burden of post-treatment effects regionally. Such data are critical for resource allocation and designing public health strategies to address cancer survivorship.

Anticipated outcomes from OPTILATER will be instrumental in informing multidisciplinary care models, fostering collaboration between oncologists, primary care physicians, mental health professionals, dietitians, and physiotherapists. The envisioned integration of care elements could set a new standard for survivorship programs nationally and internationally.

Ultimately, OPTILATER exemplifies a forward-thinking approach that addresses not only survival but thriving after cancer. Its findings promise to shift paradigms in survivorship care, emphasizing personalization, inclusivity, and long-term support, thereby transforming the future outlook for cancer survivors in Germany and setting a benchmark for global research in this critical field.

Subject of Research: Long-term care situation and quality of life of cancer survivors in Germany, focusing on physical, mental, and socio-economic challenges faced post-treatment.

Article Title: OPTILATER: optimal long-term survival after cancer – a cross-sectional study protocol for a quantitative survey on the care situation of long-term cancer survivors in Germany

Article References:
Martin, C., De Lazzari, N., Kersten, J. et al. OPTILATER: optimal long-term survival after cancer – a cross-sectional study protocol for a quantitative survey on the care situation of long-term cancer survivors in Germany. BMC Cancer 25, 1643 (2025). https://doi.org/10.1186/s12885-025-15096-7

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15096-7